22nd Century Net Total Equity Issued/Repurchased 2011-2025 | XXII
22nd Century net total equity issued/repurchased from 2011 to 2025. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
22nd Century Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2024 |
$19 |
| 2023 |
$37 |
| 2022 |
$35 |
| 2021 |
$53 |
| 2020 |
$0 |
| 2019 |
$11 |
| 2018 |
$0 |
| 2017 |
$63 |
| 2016 |
$20 |
| 2015 |
$6 |
| 2014 |
$1 |
| 2013 |
$2 |
| 2012 |
$N/A |
| 2011 |
$N/A |
| 2010 |
$1 |
| Sector |
Industry |
Market Cap |
Revenue |
| Consumer Staples |
Tobacco Products |
$0.003B |
$0.024B |
|
22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company's products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York.
|
